Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen

Journal of Medical Virology

Volumn 64, Issue 2, 2001, Pages 89-95

  Wang, Shih Min ^a,b   Liu, Ching Chuan ^a   Huang, Yi Shen ^a   Yang, Yao Jong ^a   Lei, Huan Yao ^c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

HIV antigen; HIV vaccine candidate; Oka varicella

Indexed keywords

CHICKENPOX VACCINE; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; OKA VARICELLA VACCINE; RECOMBINANT VACCINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENVELOPE GENE; GENE INSERTION; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; VARICELLA ZOSTER VIRUS; VIRUS GENOME;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CHICKENPOX VACCINE; GENETIC VECTORS; GUINEA PIGS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; PEPTIDE FRAGMENTS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS;

CAVIA; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035042923     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.1022     Document Type: Article

References (35)

1. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
2. Live attenuated varicella vaccine
3. Long-term protective immunity of the OKA strain of live varicella vaccine
4. Prime-boost immunization strategies against HIV
5. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine
6. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older
7. HIV vaccine development for the world: An idea whose time has come?
8. Chronic uveitis in guinea pigs infected with varicella-zoster virus expressing Escherichia coli beta-galactosidase
9. The complete DNA sequence of varicella-zoster virus
10. Immunization with recombinant, varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs
11. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants
12. Update on varicella vaccine
13. Novel immunogenicity of recombinant Oka varicella vaccine vector expressing hepatitis B surface antigen
14. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect
15. Varicella-zoster virus as a live vector for the expression of foreign genes
16. Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleotide analogs
17. Molecular analysis of the thymidine kinase (TK) gene of TK deficient mutants of varicella-zoster virus
18. Active and passive immunization against HIV type 1 infection in chimpanzees
19. Experimental infection of guinea pigs with varicella-zoster virus
20. Synthesis and processing of glycoproteins of varicella-zoster virus (VZV) as studied with monoclonal antibodies to VZV antigens
21. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine
22. Encouraging vaccine results from primate models of HIV type 1 infection
23. Candidate vaccines protect macaques against primate immunodeficiency viruses
24. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen
25. The immediate early proteins of varicella-zoster virus
26. Susceptibility of Oka varicella vaccine strain to antiviral drugs
27. Processing of hepatitis B virus surface antigen expressed by recombinant Oka varicella vaccine virus
28. Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV)
29. Functions of purified gB, gE:gI, and gH:gL, and their sialyl residues in varicella-zoster virus function
30. Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus
31. The varicella vaccine. Vaccine development
32. Immunization of elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen
33. Development of a live attenuated varicella vaccine
34. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
35. Immune response of guinea pigs to varicella vaccine strain (Oka) and wild strains